Boston Scientific Corp. (BSX) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration...
Boston Scientific Corp.'s revenue increased 19.9% year over year, from $16.75B to $20.07B.
Net income increased 56.4% over the same period, from $1.85B to $2.90B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt increased by 6.4% to $11.44B.
The debt-to-equity ratio stands at 0.47, indicating a moderate leverage profile.
Operating cash flow grew 32.0% to $4.53B.
Boston Scientific Corp. maintains a healthy net profit margin of 14.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $6.99B+106.2% | $584.0M | $4.89B | $1.07B | $848.0M | $33.60B | $9.05B | $18.23B |
| Q3 FY2023 | $10.52B+50.5% | $1.06B | $7.32B | $1.76B | $1.55B | $34.04B | $8.90B | $18.89B |
| Q1 FY2024 | $3.86B-63.3% | $495.0M | $2.65B | $675.0M | $164.0M | $36.67B | $10.62B | $19.93B |
| Q2 FY2024 | $7.98B+106.9% | $819.0M | $5.50B | $1.20B | $977.0M | $37.11B | $10.57B | $20.37B |
| Q1 FY2025 | $4.66B-41.5% | $674.0M | $3.21B | $921.0M | $541.0M | $40.14B | $11.31B | $22.21B |
| Q2 FY2025 | $9.72B+108.5% | $1.47B | $6.63B | $1.74B | $1.83B | $41.56B | $11.59B | $22.42B |
| Q3 FY2025 | $14.79B+52.1% | $2.23B | $10.18B | $2.79B | $3.17B | $42.71B | $11.60B | $23.39B |
| Q1 FY2026 | $5.20B-64.8% | $1.34B | $3.61B | $1.10B | $348.0M | $44.35B | $11.03B | $25.86B |
Balance Sheet Summary (Latest Period)
Total Assets
$43.67B
Total Liabilities
$19.44B
Total Equity
$24.23B
Cash & Equivalents
$1.97B
Total Debt
$11.44B
Current Assets
$8.79B
Current Liabilities
$5.44B
Retained Earnings
$5.57B